{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T14:59:19Z","timestamp":1792508359718,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06693-4","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:14:53Z","timestamp":1761534893000},"page":"4913-4930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Current scenario of allogeneic hematopoietic stem cell transplantation in adult patients with relapsed\/refractory acute myeloid leukemia: a narrative review"],"prefix":"10.1007","volume":"104","author":[{"given":"Fen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaipo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"key":"6693_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00765-5","volume":"21","author":"F Thol","year":"2020","unstructured":"Thol F, Ganser A (2020) Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol 21:66. https:\/\/doi.org\/10.1007\/s11864-020-00765-5","journal-title":"Curr Treat Options Oncol"},{"key":"6693_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.8852","author":"M Duval","year":"2010","unstructured":"Duval M, Klein JP, He W (2010) Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2010.28.8852","journal-title":"J Clin Oncol"},{"key":"6693_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D (2017) Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 129:424\u2013447. https:\/\/doi.org\/10.1182\/blood-2016-08-733196","journal-title":"Blood"},{"key":"6693_CR4","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR (2022) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 140:1345\u20131377. https:\/\/doi.org\/10.1182\/blood.2022016867","journal-title":"Blood"},{"key":"6693_CR5","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1001\/jamaoncol.2022.7605","volume":"9","author":"M Bornh\u00e4user","year":"2023","unstructured":"Bornh\u00e4user M, Schliemann C, Schetelig J (2023) Allogeneic hematopoietic cell transplantation vs standard consolidation chemotherapy in patients with intermediate-risk acute myeloid leukemia: a randomized clinical trial. JAMA Oncol 9:519\u2013526. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7605","journal-title":"JAMA Oncol"},{"key":"6693_CR6","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1038\/s41375-019-0477-x","volume":"33","author":"C Ustun","year":"2019","unstructured":"Ustun C, Le-Rademacher J, Wang H-L et al (2019) Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60\u201375 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia 33:2599\u20132609. https:\/\/doi.org\/10.1038\/s41375-019-0477-x","journal-title":"Leukemia"},{"key":"6693_CR7","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1182\/blood-2018-10-846824","volume":"133","author":"R Zeiser","year":"2019","unstructured":"Zeiser R, Vago L (2019) Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 133:1290\u20131297. https:\/\/doi.org\/10.1182\/blood-2018-10-846824","journal-title":"Blood"},{"issue":"3","key":"6693_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1182\/bloodadvances.2016000760","volume":"1","author":"L Quek","year":"2016","unstructured":"Quek L, Ferguson P, Metzner M et al (2016) Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv 1(3):193\u2013204. https:\/\/doi.org\/10.1182\/bloodadvances.2016000760","journal-title":"Blood Adv"},{"key":"6693_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","volume":"25","author":"C Toffalori","year":"2019","unstructured":"Toffalori C, Zito L, Gambacorta V et al (2019) Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med 25:603\u2013611. https:\/\/doi.org\/10.1038\/s41591-019-0400-z","journal-title":"Nat Med"},{"key":"6693_CR10","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1056\/NEJMoa0811036","volume":"361","author":"L Vago","year":"2009","unstructured":"Vago L, Perna SK, Zanussi M (2009) Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 361:478\u2013488. https:\/\/doi.org\/10.1056\/NEJMoa0811036","journal-title":"N Engl J Med"},{"key":"6693_CR11","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/leu.2014.180","volume":"29","author":"J Peccatori","year":"2015","unstructured":"Peccatori J, Forcina A, Clerici D et al (2015) Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors. Leukemia 29:396\u2013405. https:\/\/doi.org\/10.1038\/leu.2014.180","journal-title":"Leukemia"},{"issue":"11","key":"6693_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.08.008","volume":"28","author":"MA Kharfan-Dabaja","year":"2022","unstructured":"Kharfan-Dabaja MA, Reljic T, Yassine F et al (2022) Efficacy of a second allogeneic hematopoietic cell transplant in relapsed acute myeloid leukemia: results of a systematic review and meta-analysis. Transplant Cell Ther 28(11):767.e1. https:\/\/doi.org\/10.1016\/j.jtct.2022.08.008","journal-title":"Transplant Cell Ther"},{"key":"6693_CR13","unstructured":"(2022) EBMT at the 64th ASH Annual Meeting & Exposition. In: EBMT. https:\/\/www.ebmt.org\/ebmt\/news\/ebmt-64th-ash-annual-meeting-exposition. Accessed 4 Sept 2024"},{"key":"6693_CR14","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1200\/JCO.2005.06.027","volume":"23","author":"DA Breems","year":"2005","unstructured":"Breems DA, Van Putten WLJ, Huijgens PC (2005) Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 23:1969\u20131978. https:\/\/doi.org\/10.1200\/JCO.2005.06.027","journal-title":"J Clin Oncol"},{"key":"6693_CR15","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","volume":"31","author":"M Heuser","year":"2020","unstructured":"Heuser M, Ofran Y, Boissel N et al (2020) Acute myeloid leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol 31:697\u2013712. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.018","journal-title":"Ann Oncol"},{"key":"6693_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1066748","author":"Y Lu","year":"2023","unstructured":"Lu Y, Zhang J-P, Zhao Y-L (2023) Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: a single center study. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2022.1066748","journal-title":"Front Immunol"},{"key":"6693_CR17","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.18632\/oncotarget.1504","volume":"5","author":"V Folgiero","year":"2013","unstructured":"Folgiero V, Goffredo BM, Filippini P et al (2013) Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia. Oncotarget 5:2052\u20132064","journal-title":"Oncotarget"},{"key":"6693_CR18","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/bjh.12774","volume":"165","author":"N Dulphy","year":"2014","unstructured":"Dulphy N, Henry G, Hemon P et al (2014) Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol 165:722\u2013725. https:\/\/doi.org\/10.1111\/bjh.12774","journal-title":"Br J Haematol"},{"key":"6693_CR19","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/blood-2011-08-374728","volume":"118","author":"S Serra","year":"2011","unstructured":"Serra S, Horenstein AL, Vaisitti T et al (2011) CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118:6141\u20136152. https:\/\/doi.org\/10.1182\/blood-2011-08-374728","journal-title":"Blood"},{"key":"6693_CR20","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","volume":"19","author":"G Thanarajasingam","year":"2013","unstructured":"Thanarajasingam G, Kim HT, Cutler C et al (2013) Outcome and prognostic factors for patients who relapse after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 19:1713\u20131718. https:\/\/doi.org\/10.1016\/j.bbmt.2013.09.011","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.bbmt.2014.11.007","volume":"21","author":"N Bejanyan","year":"2015","unstructured":"Bejanyan N, Weisdorf DJ, Logan BR et al (2015) Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant 21:454\u2013459. https:\/\/doi.org\/10.1016\/j.bbmt.2014.11.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR22","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","volume":"4","author":"MA Kharfan-Dabaja","year":"2018","unstructured":"Kharfan-Dabaja MA, Labopin M, Polge E et al (2018) Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol 4:1245\u20131253. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2091","journal-title":"JAMA Oncol"},{"key":"6693_CR23","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/bjh.17426","volume":"193","author":"MA Kharfan-Dabaja","year":"2021","unstructured":"Kharfan-Dabaja MA, Labopin M, Brissot E et al (2021) Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia. Br J Haematol 193:592\u2013601. https:\/\/doi.org\/10.1111\/bjh.17426","journal-title":"Br J Haematol"},{"key":"6693_CR24","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/imj.13522","volume":"48","author":"ABM Lim","year":"2018","unstructured":"Lim ABM, Curley C, Fong CY et al (2018) Acute myeloid leukaemia relapsing after allogeneic haemopoietic stem cell transplantation: prognostic factors and impact of initial therapy of relapse. Intern Med J 48:276\u2013285. https:\/\/doi.org\/10.1111\/imj.13522","journal-title":"Intern Med J"},{"key":"6693_CR25","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.4004.4004","volume":"128","author":"Y Choi","year":"2016","unstructured":"Choi Y, Lee J-H, Lee K-H et al (2016) Treatment outcomes and prognostic factors of patients with relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Blood 128:4004. https:\/\/doi.org\/10.1182\/blood.V128.22.4004.4004","journal-title":"Blood"},{"key":"6693_CR26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-184701","volume":"142","author":"Y Jin","year":"2023","unstructured":"Jin Y, Fu H, Chen Y (2023) A prognostic score model for relapsed\/refractory acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 142:4237. https:\/\/doi.org\/10.1182\/blood-2023-184701","journal-title":"Blood"},{"key":"6693_CR27","doi-asserted-by":"publisher","first-page":"e167","DOI":"10.1016\/j.clml.2018.02.009","volume":"18","author":"S-S Park","year":"2018","unstructured":"Park S-S, Kim H-J, Min KI (2018) Prognostic prediction model for second allogeneic stem-cell transplantation in patients with relapsed acute myeloid leukemia: single-center report. Clin Lymphoma Myeloma Leuk 18:e167\u2013e182. https:\/\/doi.org\/10.1016\/j.clml.2018.02.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6693_CR28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205561","volume":"144","author":"R Ma","year":"2024","unstructured":"Ma R, Zhu X, Zhang J (2024) Changing donor was critical for the successful salvage second transplantation for graft failure after the first allogeneic stem cell transplantation: a Chinese multicenter retrospective study. Blood 144:2109. https:\/\/doi.org\/10.1182\/blood-2024-205561","journal-title":"Blood"},{"key":"6693_CR29","doi-asserted-by":"publisher","DOI":"10.2196\/36490","volume":"24","author":"Y El Alaoui","year":"2022","unstructured":"El Alaoui Y, Elomri A, Qaraqe M (2022) A review of artificial intelligence applications in hematology management: current practices and future prospects. J Med Internet Res 24:e36490. https:\/\/doi.org\/10.2196\/36490","journal-title":"J Med Internet Res"},{"issue":"3","key":"6693_CR30","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3324\/haematol.2021.280027","volume":"108","author":"J-N Eckardt","year":"2022","unstructured":"Eckardt J-N, R\u00f6llig C, Metzeler K (2022) Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning. Haematologica 108(3):690\u2013704. https:\/\/doi.org\/10.3324\/haematol.2021.280027","journal-title":"Haematologica"},{"key":"6693_CR31","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V et al (2020) Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med 383:617\u2013629. https:\/\/doi.org\/10.1056\/NEJMoa2012971","journal-title":"N Engl J Med"},{"key":"6693_CR32","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/blood.2020004856","volume":"135","author":"AH Wei","year":"2020","unstructured":"Wei AH, Montesinos P, Ivanov V et al (2020) Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood 135:2137\u20132145. https:\/\/doi.org\/10.1182\/blood.2020004856","journal-title":"Blood"},{"key":"6693_CR33","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL et al (2017) Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med 377:454\u2013464. https:\/\/doi.org\/10.1056\/NEJMoa1614359","journal-title":"N Engl J Med"},{"key":"6693_CR34","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S et al (2022) Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med 386:1519\u20131531. https:\/\/doi.org\/10.1056\/NEJMoa2117344","journal-title":"N Engl J Med"},{"key":"6693_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-017-0498-8","volume":"10","author":"E Brissot","year":"2017","unstructured":"Brissot E, Labopin M, Stelljes M et al (2017) Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the acute leukemia working party of the EBMT. J Hematol Oncol 10:130. https:\/\/doi.org\/10.1186\/s13045-017-0498-8","journal-title":"J Hematol Oncol"},{"key":"6693_CR36","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2022-159962","volume":"140","author":"M Stelljes","year":"2022","unstructured":"Stelljes M, Middeke JM, Bug G et al (2022) In patients with relapsed\/refractory AML sequential conditioning and immediate allogeneic stem cell transplantation (allo-HCT) results in similar overall and leukemia-free survival compared to intensive remission induction chemotherapy followed by Allo-HCT: results from the randomized phase III ASAP trial. Blood 140:9\u201311. https:\/\/doi.org\/10.1182\/blood-2022-159962","journal-title":"Blood"},{"key":"6693_CR37","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1016\/j.bbmt.2014.05.013","volume":"20","author":"GL Chen","year":"2014","unstructured":"Chen GL, Liu H, Zhang Y et al (2014) Early versus late preemptive allogeneic hematopoietic cell transplantation for relapsed or refractory acute myeloid leukemia. Biol Blood Marrow Transplant 20:1369\u20131374. https:\/\/doi.org\/10.1016\/j.bbmt.2014.05.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/hematology.2022000326","volume":"2022","author":"SR Spellman","year":"2022","unstructured":"Spellman SR (2022) Hematology 2022-what is complete HLA match in 2022? Hematology 2022:83\u201389. https:\/\/doi.org\/10.1182\/hematology.2022000326","journal-title":"Hematology"},{"key":"6693_CR39","doi-asserted-by":"publisher","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","volume":"6","author":"R Shouval","year":"2019","unstructured":"Shouval R, Fein JA, Labopin M et al (2019) Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European society for blood and marrow transplantation registry retrospective analysis. Lancet Haematol 6:e573\u2013e584. https:\/\/doi.org\/10.1016\/S2352-3026(19)30158-9","journal-title":"Lancet Haematol"},{"key":"6693_CR40","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1038\/s41375-019-0686-3","volume":"34","author":"S Yu","year":"2020","unstructured":"Yu S, Huang F, Wang Y et al (2020) Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia 34:1433\u20131443. https:\/\/doi.org\/10.1038\/s41375-019-0686-3","journal-title":"Leukemia"},{"key":"6693_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"X Zhang","year":"2021","unstructured":"Zhang X, Chen J, Han M-Z et al (2021) The consensus from the Chinese society of hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol 14:145. https:\/\/doi.org\/10.1186\/s13045-021-01159-2","journal-title":"J Hematol Oncol"},{"key":"6693_CR42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","volume":"5","author":"AE DeZern","year":"2021","unstructured":"DeZern AE, Franklin C, Tsai H-L et al (2021) Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide. Blood Adv 5:1360\u20131368. https:\/\/doi.org\/10.1182\/bloodadvances.2020003922","journal-title":"Blood Adv"},{"key":"6693_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.09.014","author":"QY Wang","year":"2024","unstructured":"Wang QY, Han YF, Li YH et al (2024) A novel prognostic scoring system for AML patients undergoing allogeneic hematopoietic stem cell transplantation with real world validation. J Adv Res. https:\/\/doi.org\/10.1016\/j.jare.2024.09.014","journal-title":"J Adv Res"},{"key":"6693_CR44","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1016\/j.bbmt.2020.07.020","volume":"26","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2020","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Labopin M, Tischer J et al (2020) Flamsa-based reduced-intensity conditioning versus myeloablative conditioning in younger patients with relapsed\/refractory acute myeloid leukemia with active disease at the time of allogeneic stem cell transplantation: an analysis from the acute leukemia working party of the European society for blood and marrow transplantation. Biol Blood Marrow Transplant 26:2165\u20132173. https:\/\/doi.org\/10.1016\/j.bbmt.2020.07.020","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR45","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41409-022-01611-y","volume":"57","author":"E Rodr\u00edguez-Arbol\u00ed","year":"2022","unstructured":"Rodr\u00edguez-Arbol\u00ed E, Labopin M, Eder M et al (2022) Augmented FLAMSA-Bu versus FluBu2 reduced-intensity conditioning in patients with active relapsed\/refractory acute myeloid leukemia: an EBMT analysis. Bone Marrow Transplant 57:934\u2013941. https:\/\/doi.org\/10.1038\/s41409-022-01611-y","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/10428194.2020.1827248","volume":"62","author":"T Heinicke","year":"2021","unstructured":"Heinicke T, Labopin M, Polge E et al (2021) Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed\/refractory acute myelogenous leukemia \u2013 a study of the acute leukemia working party of the EBMT. Leuk Lymphoma 62:399\u2013409. https:\/\/doi.org\/10.1080\/10428194.2020.1827248","journal-title":"Leuk Lymphoma"},{"key":"6693_CR47","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1007\/s00277-020-04074-7","volume":"99","author":"A Le Bourgeois","year":"2020","unstructured":"Le Bourgeois A, Labopin M, Mar\u00e7ais A et al (2020) Sequential allogeneic hematopoietic stem cell transplantation for active refractory\/relapsed myeloid malignancies: results of a reduced-intensity conditioning preceded by clofarabine and cytosine arabinoside, a retrospective study on behalf of the SFGM-TC. Ann Hematol 99:1855\u20131862. https:\/\/doi.org\/10.1007\/s00277-020-04074-7","journal-title":"Ann Hematol"},{"key":"6693_CR48","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1038\/s41409-022-01703-9","volume":"57","author":"F Guijarro","year":"2022","unstructured":"Guijarro F, Bataller A, Diaz-Bey\u00e1 M et al (2022) Long-term outcomes in patients with relapsed\/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplant 57:1304\u20131312. https:\/\/doi.org\/10.1038\/s41409-022-01703-9","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR49","doi-asserted-by":"publisher","first-page":"127.e1","DOI":"10.1016\/j.jtct.2022.11.022","volume":"29","author":"M Klimentova","year":"2023","unstructured":"Klimentova M, Shelikhova L, Ilushina M et al (2023) Targeted therapy with venetoclax and daratumumab as part of HSCT preparative regimen in children with chemorefractory acute myeloid leukemia. Transplant Cell Ther 29:127.e1-127.e9. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.022","journal-title":"Transplant Cell Ther"},{"key":"6693_CR50","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1002\/ijc.34419","volume":"152","author":"X Tong","year":"2023","unstructured":"Tong X, Li M, Jin J et al (2023) Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome. Int J Cancer 152:2123\u20132133. https:\/\/doi.org\/10.1002\/ijc.34419","journal-title":"Int J Cancer"},{"key":"6693_CR51","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000848420.57492.c3","volume":"6","author":"S Chen","year":"2022","unstructured":"Chen S, Zhang X, Zhai W et al (2022) P1390: THE EFFICACY AND SAFETY OF MODIFIED MELPHALAN AND BUSULFAN-BASED REGIMEN FOR ALLOGENEIC TRANSPLANTATION IN REFRACTORY\/RELAPSED AML PATIENTS. HemaSphere 6:1274. https:\/\/doi.org\/10.1097\/01.HS9.0000848420.57492.c3","journal-title":"HemaSphere"},{"key":"6693_CR52","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.4149\/neo_2021_210426N573","volume":"68","author":"Y Sun","year":"2021","unstructured":"Sun Y, Zhang J, Long B et al (2021) A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed\/refractory acute myeloid leukemia. Neoplasma 68:1351\u20131358. https:\/\/doi.org\/10.4149\/neo_2021_210426N573","journal-title":"Neoplasma"},{"key":"6693_CR53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170244","volume":"140","author":"R Al Hamed","year":"2022","unstructured":"Al Hamed R, Labopin M, Bethge W et al (2022) Amsa\/ARA-C followed by TBI 4 gy or high dose chemotherapy conditioning regimens in primary refractory AML - Significantly worse outcomes in younger patients conditioned with 4 gy TBI. Blood 140:10455\u201310457. https:\/\/doi.org\/10.1182\/blood-2022-170244","journal-title":"Blood"},{"key":"6693_CR54","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","volume":"394","author":"P Moreau","year":"2019","unstructured":"Moreau P, Attal M, Hulin C et al (2019) Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet 394:29\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)31240-1","journal-title":"Lancet"},{"key":"6693_CR55","doi-asserted-by":"crossref","first-page":"P685","DOI":"10.2967\/jnumed.122.265131","volume":"64","author":"N Pandit-Taskar","year":"2023","unstructured":"Pandit-Taskar N, Natwa M, Chen M-K et al (2023) Individualized dosing for high-dose targeted radiation of hematopoietic cells with Iomab-B (I131-apamistamab) prior to HCT in relapsed\/refractory acute myeloid leukemia (R\/R AML): safety and efficacy results from the pivotal phase 3 SIERRA trial. J Nucl Med 64:P685\u2013P685","journal-title":"J Nucl Med"},{"key":"6693_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2024.e33937","volume":"10","author":"J Liu","year":"2024","unstructured":"Liu J, Xu M, Zhang X et al (2024) CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory\/relapsed B-cell acute lymphoblastic leukemia. Heliyon 10:e33937. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33937","journal-title":"Heliyon"},{"key":"6693_CR57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-180387","volume":"142","author":"X Zhang","year":"2023","unstructured":"Zhang X, Lv H, Xiao X et al (2023) A phase I clinical trial of CLL-1 CAR-T cells for the treatment of relapsed\/refractory acute myeloid leukemia in adults. Blood 142:2106. https:\/\/doi.org\/10.1182\/blood-2023-180387","journal-title":"Blood"},{"key":"6693_CR58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-177867","volume":"142","author":"M Wermke","year":"2023","unstructured":"Wermke M, Metzelder S, Kraus S (2023) Updated results from a phase I dose escalation study of the rapidly-switchable universal CAR-T therapy UniCAR-T-CD123 in relapsed\/refractory AML. Blood 142:3465. https:\/\/doi.org\/10.1182\/blood-2023-177867","journal-title":"Blood"},{"key":"6693_CR59","doi-asserted-by":"publisher","first-page":"4272","DOI":"10.1182\/blood-2024-209157","volume":"144","author":"V Bharathi","year":"2024","unstructured":"Bharathi V, Bataller A, Bazinet A et al (2024) Phase Ib\/II study of CPX-351 plus venetoclax in patients with Relapsed\/Refractory acute myeloid leukemia (AML)CPX-351. Blood 144:4272. https:\/\/doi.org\/10.1182\/blood-2024-209157","journal-title":"Blood"},{"key":"6693_CR60","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/blood-2023-188489","volume":"142","author":"H Wang","year":"2023","unstructured":"Wang H, Wei X, Jiang Q et al (2023) Safety and efficacy of Lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in relapsed or refractory (R\/R) or Treatment-Na\u00efve (TN) patients (Pts) with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or other myeloid neoplasmslisaftoclax (APG-2575). Blood 142:2925. https:\/\/doi.org\/10.1182\/blood-2023-188489","journal-title":"Blood"},{"key":"6693_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S et al (2023) Venetoclax combined with azacitidine and homoharringtonine in relapsed\/refractory AML: a multicenter, phase 2 trial. J Hematol Oncol 16:42. https:\/\/doi.org\/10.1186\/s13045-023-01437-1","journal-title":"J Hematol Oncol"},{"key":"6693_CR62","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-205980","volume":"144","author":"AS Stein","year":"2024","unstructured":"Stein AS, Zhang J, Ghoda LY et al (2024) Phase 1 trial of Navitoclax\/Venetoclax\/Decitabine combination in relapsed\/refractory (R\/R) acute myeloid leukemia (AML). Blood 144:4264. https:\/\/doi.org\/10.1182\/blood-2024-205980","journal-title":"Blood"},{"key":"6693_CR63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1182\/blood-2024-207264","volume":"144","author":"X Dou","year":"2024","unstructured":"Dou X, Chen S, Wu D (2024) Prospective study of avapritinib in patients with Relapsed\/Refractory or MRD-Positive Core-Binding factor acute myeloid leukemia with KIT mutationsavapritinib. Blood 144:222. https:\/\/doi.org\/10.1182\/blood-2024-207264","journal-title":"Blood"},{"key":"6693_CR64","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood.2021012412","volume":"141","author":"Z DeFilipp","year":"2023","unstructured":"DeFilipp Z, Chen Y-B (2023) How i treat with maintenance therapy after allogeneic HCT. Blood 141:39\u201348. https:\/\/doi.org\/10.1182\/blood.2021012412","journal-title":"Blood"},{"key":"6693_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01017-7","volume":"14","author":"L Xuan","year":"2021","unstructured":"Xuan L, Liu Q (2021) Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. J Hematol Oncol 14:4. https:\/\/doi.org\/10.1186\/s13045-020-01017-7","journal-title":"J Hematol Oncol"},{"key":"6693_CR66","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.801632","volume":"9","author":"S Kungwankiattichai","year":"2022","unstructured":"Kungwankiattichai S, Ponvilawan B, Roy C et al (2022) Maintenance with hypomethylating agents after allogeneic stem cell transplantation in acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis. Front Med 9:801632. https:\/\/doi.org\/10.3389\/fmed.2022.801632","journal-title":"Front Med"},{"key":"6693_CR67","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S et al (2020) Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial. J Clin Oncol 38:4249\u20134259. https:\/\/doi.org\/10.1200\/JCO.19.03277","journal-title":"J Clin Oncol"},{"key":"6693_CR68","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1038\/leu.2017.242","volume":"31","author":"G Bug","year":"2017","unstructured":"Bug G, Burchert A, Wagner E-M et al (2017) Phase I\/II study of the deacetylase inhibitor Panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial). Leukemia 31:2523\u20132525. https:\/\/doi.org\/10.1038\/leu.2017.242","journal-title":"Leukemia"},{"key":"6693_CR69","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13016","author":"M Kirschbaum","year":"2014","unstructured":"Kirschbaum M, Gojo I, Goldberg SL et al (2014) A phase 1 clinical trial of Vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Br J Haematol. https:\/\/doi.org\/10.1111\/bjh.13016","journal-title":"Br J Haematol"},{"key":"6693_CR70","doi-asserted-by":"publisher","first-page":"2793","DOI":"10.3109\/10428194.2015.1018248","volume":"56","author":"J How","year":"2015","unstructured":"How J, Minden MD, Brian L et al (2015) A phase I trial of two sequence-specific schedules of decitabine and vorinostat in patients with acute myeloid leukemia. Leuk Lymphoma 56:2793\u20132802. https:\/\/doi.org\/10.3109\/10428194.2015.1018248","journal-title":"Leuk Lymphoma"},{"key":"6693_CR71","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.763.763","volume":"118","author":"G Garcia-Manero","year":"2011","unstructured":"Garcia-Manero G, Tambaro FP, Bekele N et al (2011) Final report of a phase II trial of Vorinostat with Idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Blood 118:763. https:\/\/doi.org\/10.1182\/blood.V118.21.763.763","journal-title":"Blood"},{"key":"6693_CR72","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/bjh.12359","volume":"162","author":"GJ Ossenkoppele","year":"2013","unstructured":"Ossenkoppele GJ, Lowenberg B, Zachee P et al (2013) A phase I first-in-human study with tefinostat \u2013 a monocyte\/macrophage targeted histone deacetylase inhibitor \u2013 in patients with advanced haematological malignancies. Br J Haematol 162:191\u2013201. https:\/\/doi.org\/10.1111\/bjh.12359","journal-title":"Br J Haematol"},{"key":"6693_CR73","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1158\/1078-0432.CCR-11-3165","volume":"18","author":"U Banerji","year":"2012","unstructured":"Banerji U, van Doorn L, Papadatos-Pastos D et al (2012) A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res 18:2687\u20132694. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-3165","journal-title":"Clin Cancer Res"},{"key":"6693_CR74","doi-asserted-by":"publisher","first-page":"e600","DOI":"10.1016\/S2352-3026(23)00117-5","volume":"10","author":"L Xuan","year":"2023","unstructured":"Xuan L, Wang Y, Yang K et al (2023) Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trial. Lancet Haematol 10:e600\u2013e611. https:\/\/doi.org\/10.1016\/S2352-3026(23)00117-5","journal-title":"Lancet Haematol"},{"key":"6693_CR75","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1182\/blood-2018-08-869453","volume":"133","author":"RF Schlenk","year":"2019","unstructured":"Schlenk RF, Weber D, Fiedler W et al (2019) Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood 133:840\u2013851. https:\/\/doi.org\/10.1182\/blood-2018-08-869453","journal-title":"Blood"},{"key":"6693_CR76","doi-asserted-by":"publisher","first-page":"7008","DOI":"10.1200\/JCO.2016.34.15_suppl.7008","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Kantarjian HM, Kadia TM et al (2016) Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML. JCO 34:7008\u20137008. https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.7008","journal-title":"JCO"},{"key":"6693_CR77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.389.389","volume":"124","author":"JK Randhawa","year":"2014","unstructured":"Randhawa JK, Kantarjian HM, Borthakur G (2014) Results of a phase II study of crenolanib in relapsed\/refractory acute myeloid leukemia patients (Pts) with activating FLT3 mutations. Blood 124:389. https:\/\/doi.org\/10.1182\/blood.V124.21.389.389","journal-title":"Blood"},{"key":"6693_CR78","doi-asserted-by":"publisher","DOI":"10.1097\/01.HS9.0000845252.68424.50","volume":"6","author":"W Yu","year":"2022","unstructured":"Yu W, Wei X, Ge Z et al (2022) P591: Preliminary results of a phase I study of clifutinib, a highly selective, potent oral FLT-3 inhibitor, in patinets with FLT3-mutated relapsed or refractory acute myeloid leukemia. HemaSphere 6:490. https:\/\/doi.org\/10.1097\/01.HS9.0000845252.68424.50","journal-title":"HemaSphere"},{"key":"6693_CR79","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-124322","volume":"134","author":"MJ Levis","year":"2019","unstructured":"Levis MJ, Hamadani M, Logan BR (2019) BMT CTN protocol 1506: a phase 3 trial of gilteritinib as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3-ITD\u2009+\u2009AML. Blood 134:4602. https:\/\/doi.org\/10.1182\/blood-2019-124322","journal-title":"Blood"},{"key":"6693_CR80","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1007\/s10147-021-02006-7","volume":"26","author":"N Hosono","year":"2021","unstructured":"Hosono N, Yokoyama H, Aotsuka N et al (2021) Gilteritinib versus chemotherapy in Japanese patients with FLT3-mutated relapsed\/refractory acute myeloid leukemia. Int J Clin Oncol 26:2131\u20132141. https:\/\/doi.org\/10.1007\/s10147-021-02006-7","journal-title":"Int J Clin Oncol"},{"key":"6693_CR81","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902688","author":"AE Perl","year":"2019","unstructured":"Perl AE, Martinelli G, Cortes JE et al (2019) Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa1902688","journal-title":"N Engl J Med"},{"key":"6693_CR82","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1200\/JCO.22.00602","volume":"40","author":"N Daver","year":"2022","unstructured":"Daver N, Perl AE, Maly J et al (2022) Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia. JCO 40:4048\u20134059. https:\/\/doi.org\/10.1200\/JCO.22.00602","journal-title":"JCO"},{"key":"6693_CR83","doi-asserted-by":"publisher","first-page":"5857","DOI":"10.1182\/bloodadvances.2022008632","volume":"6","author":"AT Fathi","year":"2022","unstructured":"Fathi AT, Kim HT, Soiffer RJ et al (2022) Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies. Blood Adv 6:5857\u20135865. https:\/\/doi.org\/10.1182\/bloodadvances.2022008632","journal-title":"Blood Adv"},{"key":"6693_CR84","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1182\/blood-2022-169964","volume":"140","author":"A Salhotra","year":"2022","unstructured":"Salhotra A, Bejanyan N, Yang D et al (2022) Multicenter pilot clinical trial of enasidenib as maintenance therapy after allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia (AML) carrying IDH2 mutations. Blood 140:1890\u20131892. https:\/\/doi.org\/10.1182\/blood-2022-169964","journal-title":"Blood"},{"key":"6693_CR85","doi-asserted-by":"publisher","first-page":"3636","DOI":"10.1111\/cas.15048","volume":"112","author":"Y Wei","year":"2021","unstructured":"Wei Y, Xiong X, Li X et al (2021) Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome. Cancer Sci 112:3636\u20133644. https:\/\/doi.org\/10.1111\/cas.15048","journal-title":"Cancer Sci"},{"issue":"8","key":"6693_CR86","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41409-023-01987-5","volume":"58","author":"A Kent","year":"2023","unstructured":"Kent A, Schwartz M, McMahon C et al (2023) Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse. Bone Marrow Transplant 58(8):849\u2013854. https:\/\/doi.org\/10.1038\/s41409-023-01987-5","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR87","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1182\/bloodadvances.2023012120","volume":"8","author":"JS Garcia","year":"2024","unstructured":"Garcia JS, Kim HT, Murdock HM et al (2024) Prophylactic maintenance with venetoclax\/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML. Blood Adv 8:978\u2013990. https:\/\/doi.org\/10.1182\/bloodadvances.2023012120","journal-title":"Blood Adv"},{"key":"6693_CR88","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.bbmt.2014.07.010","volume":"20","author":"A Takami","year":"2014","unstructured":"Takami A, Yano S, Yokoyama H et al (2014) Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the adult acute myeloid leukemia working group of the Japan society for hematopoietic cell transplantation. Biol Blood Marrow Transplant 20:1785\u20131790. https:\/\/doi.org\/10.1016\/j.bbmt.2014.07.010","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR89","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/bjh.15691","volume":"184","author":"C Schmid","year":"2019","unstructured":"Schmid C, Labopin M, Schaap N et al (2019) Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia \u2013 a matched pair analysis by the acute leukaemia working party of EBMT. Br J Haematol 184:782\u2013787. https:\/\/doi.org\/10.1111\/bjh.15691","journal-title":"Br J Haematol"},{"issue":"11","key":"6693_CR90","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/bmt.2016.167","volume":"51","author":"P Tsirigotis","year":"2016","unstructured":"Tsirigotis P, Byrne M, Schmid C (2016) Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT. Bone Marrow Transplant 51(11):1431\u20131438. https:\/\/doi.org\/10.1038\/bmt.2016.167","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR91","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/bmt.2015.234","volume":"51","author":"Z Jedlickova","year":"2016","unstructured":"Jedlickova Z, Schmid C, Koenecke C et al (2016) Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant 51:663\u2013667. https:\/\/doi.org\/10.1038\/bmt.2015.234","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR92","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1007\/s11427-019-1610-2","volume":"63","author":"Y Wang","year":"2020","unstructured":"Wang Y, Liu Q-F, Wu D-P (2020) Impact of prophylactic\/preemptive donor lymphocyte infusion and intensified conditioning for relapsed\/refractory leukemia: a real-world study. Sci China Life Sci 63:1552\u20131564. https:\/\/doi.org\/10.1007\/s11427-019-1610-2","journal-title":"Sci China Life Sci"},{"key":"6693_CR93","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41409-023-02137-7","volume":"59","author":"L Yang","year":"2024","unstructured":"Yang L, Lai X, Yang T et al (2024) Prophylactic versus preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study. Bone Marrow Transplant 59:85\u201392. https:\/\/doi.org\/10.1038\/s41409-023-02137-7","journal-title":"Bone Marrow Transplant"},{"key":"6693_CR94","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.bbmt.2017.04.028","volume":"23","author":"C-H Yan","year":"2017","unstructured":"Yan C-H, Liu Q, Wu D (2017) Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and Graft-versus-Host disease\u2013guided multiple DLIs could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory\/relapsed acute leukemia. Biol Blood Marrow Transplant 23:1311\u20131319. https:\/\/doi.org\/10.1016\/j.bbmt.2017.04.028","journal-title":"Biol Blood Marrow Transplant"},{"key":"6693_CR95","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3324\/haematol.2019.219790","volume":"105","author":"B Dholaria","year":"2020","unstructured":"Dholaria B, Savani BN, Labopin M et al (2020) Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT. Haematologica 105:47\u201358. https:\/\/doi.org\/10.3324\/haematol.2019.219790","journal-title":"Haematologica"},{"key":"6693_CR96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112699","volume":"13","author":"P Tsirigotis","year":"2021","unstructured":"Tsirigotis P, Gkirkas K, Kitsiou V et al (2021) Repetitively administered low-dose donor lymphocyte infusion for prevention of relapse after allogeneic stem cell transplantation in patients with high-risk acute leukemia. Cancers 13:2699. https:\/\/doi.org\/10.3390\/cancers13112699","journal-title":"Cancers"},{"key":"6693_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.554503","author":"Q Su","year":"2021","unstructured":"Su Q, Fan Z, Huang F et al (2021) Comparison of two strategies for prophylactic donor lymphocyte infusion in patients with refractory\/relapsed acute leukemia. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2021.554503","journal-title":"Front Oncol"},{"key":"6693_CR98","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1007\/s00277-021-04494-z","volume":"100","author":"AR Rettig","year":"2021","unstructured":"Rettig AR, Ihorst G, Bertz H et al (2021) Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis. Ann Hematol 100:2339\u20132350. https:\/\/doi.org\/10.1007\/s00277-021-04494-z","journal-title":"Ann Hematol"},{"key":"6693_CR99","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.bbmt.2013.11.020","volume":"20","author":"AM Zeidan","year":"2014","unstructured":"Zeidan AM, Forde PM, Symons H et al (2014) HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 20:314\u2013318. https:\/\/doi.org\/10.1016\/j.bbmt.2013.11.020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"6693_CR100","doi-asserted-by":"publisher","first-page":"S134","DOI":"10.1016\/j.jcyt.2020.03.262","volume":"22","author":"F Otegbeye","year":"2020","unstructured":"Otegbeye F, Ramsey C, Fox R et al (2020) Manufacturing a donor lymphocyte product depleted of TCR-\u03b1\u03b2 T cells and CD19\u2009+\u2009B cells for prophylactic infusion following allogeneic stem cell transplantation. Cytotherapy 22:S134. https:\/\/doi.org\/10.1016\/j.jcyt.2020.03.262","journal-title":"Cytotherapy"},{"key":"6693_CR101","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood.2020009471","volume":"137","author":"PD Lulla","year":"2021","unstructured":"Lulla PD, Naik S, Vasileiou S et al (2021) Clinical effects of administering leukemia-specific donor T cells to patients with AML\/MDS after allogeneic transplant. Blood 137:2585\u20132597. https:\/\/doi.org\/10.1182\/blood.2020009471","journal-title":"Blood"},{"key":"6693_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.949534","author":"X Li","year":"2022","unstructured":"Li X, Wang W, Zhang X, Wu Y (2022) Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: a meta-analysis. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2022.949534","journal-title":"Front Oncol"},{"key":"6693_CR103","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F et al (2020) Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol 21:1201\u20131212. https:\/\/doi.org\/10.1016\/S1470-2045(20)30455-1","journal-title":"Lancet Oncol"},{"key":"6693_CR104","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1158\/1078-0432.CCR-23-0182","volume":"29","author":"AT Fathi","year":"2023","unstructured":"Fathi AT, Kim HT, Soiffer RJ et al (2023) Multicenter phase I trial of Ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia. Clin Cancer Res 29:2034\u20132042. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-0182","journal-title":"Clin Cancer Res"},{"key":"6693_CR105","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11259-6","volume":"23","author":"Y Du","year":"2023","unstructured":"Du Y, Li C, Zhao Z et al (2023) Efficacy and safety of venetoclax combined with hypomethylating agents for relapse of acute myeloid leukemia and myelodysplastic syndrome post allogeneic hematopoietic stem cell transplantation: a systematic review and meta-analysis. BMC Cancer 23:764. https:\/\/doi.org\/10.1186\/s12885-023-11259-6","journal-title":"BMC Cancer"},{"key":"6693_CR106","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1007\/s00277-021-04616-7","volume":"100","author":"N Shah","year":"2021","unstructured":"Shah N, Rakszawski K, Nickolich M et al (2021) Improved outcome in AML relapse after allogeneic transplant with high-intensity chemotherapy followed by 2nd allogeneic stem cell transplant or donor lymphocyte infusion. Ann Hematol 100:2585\u20132592. https:\/\/doi.org\/10.1007\/s00277-021-04616-7","journal-title":"Ann Hematol"},{"key":"6693_CR107","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.3324\/haematol.2022.281877","volume":"108","author":"Y Yerushalmi","year":"2022","unstructured":"Yerushalmi Y, Shem-Tov N, Danylesko I et al (2022) Second hematopoietic stem cell transplantation as salvage therapy for relapsed acute myeloid leukemia\/myelodysplastic syndromes after a first transplantation. Haematologica 108:1782\u20131792. https:\/\/doi.org\/10.3324\/haematol.2022.281877","journal-title":"Haematologica"},{"key":"6693_CR108","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","volume":"27","author":"FF Yalniz","year":"2021","unstructured":"Yalniz FF, Saliba RM, Greenbaum U et al (2021) Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia. Transplant Cell Ther 27:689\u2013695. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.007","journal-title":"Transplant Cell Ther"},{"key":"6693_CR109","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s12185-019-02709-8","volume":"110","author":"K Usuki","year":"2019","unstructured":"Usuki K, Handa H, Choi I et al (2019) Safety and pharmacokinetics of Quizartinib in Japanese patients with relapsed or refractory acute myeloid leukemia in a phase 1 study. Int J Hematol 110:654\u2013664. https:\/\/doi.org\/10.1007\/s12185-019-02709-8","journal-title":"Int J Hematol"},{"key":"6693_CR110","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00604-2","volume":"12","author":"S Venugopal","year":"2022","unstructured":"Venugopal S, Takahashi K, Daver N et al (2022) Efficacy and safety of enasidenib and Azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy. Blood Cancer J 12:1\u20137. https:\/\/doi.org\/10.1038\/s41408-021-00604-2","journal-title":"Blood Cancer J"},{"key":"6693_CR111","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1200\/JCO.20.03736","volume":"39","author":"CD DiNardo","year":"2021","unstructured":"DiNardo CD, Lachowiez CA, Takahashi K et al (2021) Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia. J Clin Oncol 39:2768\u20132778. https:\/\/doi.org\/10.1200\/JCO.20.03736","journal-title":"J Clin Oncol"},{"key":"6693_CR112","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/joim.13738","volume":"295","author":"S Yu","year":"2024","unstructured":"Yu S, Zhang Y, Yu G et al (2024) Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory\/relapsed acute myeloid leukemia with FLT3-ITD: a multicenter phase 2 study. J Intern Med 295:216\u2013228. https:\/\/doi.org\/10.1111\/joim.13738","journal-title":"J Intern Med"},{"key":"6693_CR113","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V et al (2019) Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood 133:7\u201317. https:\/\/doi.org\/10.1182\/blood-2018-08-868752","journal-title":"Blood"},{"key":"6693_CR114","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S et al (2019) Efficacy, Safety, and biomarkers of response to Azacitidine and nivolumab in Relapsed\/Refractory acute myeloid leukemia: A Nonrandomized, Open-Label, phase II study. Cancer Discov 9:370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0774","journal-title":"Cancer Discov"},{"key":"6693_CR115","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","volume":"2","author":"JF Zeidner","year":"2021","unstructured":"Zeidner JF, Vincent BG, Ivanova A et al (2021) Phase II trial of pembrolizumab after high-dose cytarabine in relapsed\/refractory acute myeloid leukemia. Blood Cancer Discov 2:616\u2013629. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0070","journal-title":"Blood Cancer Discov"},{"key":"6693_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106385","volume":"95","author":"AD Goldberg","year":"2020","unstructured":"Goldberg AD, Atallah E, Rizzieri D et al (2020) Camidanlumab tesirine, an antibody-drug conjugate, in relapsed\/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: a phase I study. Leuk Res 95:106385. https:\/\/doi.org\/10.1016\/j.leukres.2020.106385","journal-title":"Leuk Res"},{"key":"6693_CR117","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282570","volume":"108","author":"T Schroeder","year":"2023","unstructured":"Schroeder T, Stelljes M, Christopeit M et al (2023) Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial. Haematologica 108:3001. https:\/\/doi.org\/10.3324\/haematol.2022.282570","journal-title":"Haematologica"},{"key":"6693_CR118","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01911-9","volume":"40","author":"Y Wei","year":"2023","unstructured":"Wei Y, Wang L, Zhu C et al (2023) A phase II study of chidamide, cytarabine, aclarubicin, granulocyte colony-stimulating factor, and donor lymphocyte infusion for relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Med Oncol 40:77. https:\/\/doi.org\/10.1007\/s12032-022-01911-9","journal-title":"Med Oncol"},{"key":"6693_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26683-0","volume":"12","author":"N El Khawanky","year":"2021","unstructured":"El Khawanky N, Hughes A, Yu W (2021) Demethylating therapy increases anti-CD123 CAR t cell cytotoxicity against acute myeloid leukemia. Nat Commun 12:6436. https:\/\/doi.org\/10.1038\/s41467-021-26683-0","journal-title":"Nat Commun"},{"key":"6693_CR120","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3760\/cma.j.issn.0253-2727.2016.08.020","volume":"37","author":"Y Wang","year":"2016","unstructured":"Wang Y, Huang XJ (2016) [Haploidentical transplantation for the treatment of intermediate- or high- risk acute myeloid leukemia in first complete remission: guideline and practice]. Zhonghua Xue Ye Xue Za Zhi 37:721\u2013724. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2016.08.020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06693-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06693-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T20:02:41Z","timestamp":1763236961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06693-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":120,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6693"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06693-4","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"24 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"No financial or personal relationships with other people or organizations have influenced the work reported in this manuscript. All authors have reviewed and approved the final version of the manuscript and its submission for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}